Previous studies have demonstrated that ROS-induced stabilization of hypoxia-inducible factor 1-alpha (HIF-1α) in the bone marrow microenvironment of multiple myeloma patients promotes the expression of proangiogenic genes and contributes to resistance to immunomodulatory drugs and proteasome inhibitors [29]. The gene discussed is HIF1A; the disease is plasma cell myeloma.